文献速递姑息放疗与转移瘤

超高龄(90岁以上)患者的放疗:分次策略演变、症状缓解与生存

Radiotherapy at the limits of age: evolving fractionation strategies, symptom palliation, and survival in nonagenarians.
PubMed 文献 · Radiother Oncol · 2026-05-22

单中心回顾性队列纳入2005–2023年接受放疗的199例90岁以上患者,42%为根治性、58%为姑息性。中位总生存11个月(姑息治疗7个月),1年和5年总生存率分别为47%和11%。73%患者症状改善,肿瘤相关出血改善率95%、溃疡80%、疼痛65%。急性≥2级毒性21%(3级5%)。

要点

  • 90岁以上患者放疗中位总生存11个月,姑息治疗为7个月。
  • 症状改善率73%,出血和溃疡改善率分别达95%和80%。
  • 大分割和超大分割放疗的≥2级毒性几率低于常规分割。

核心结论

  • 在经选择的90岁以上患者中,放疗可实现较高的症状缓解率且严重毒性低。
  • 大分割放疗耐受良好,对生存无明确不利影响。

研究设计与样本

  • 单中心回顾性队列研究,纳入2005–2023年接受放疗的199例90岁以上患者。
  • 分次方案分为常规分割(NF-RT)、大分割(HF-RT:>2Gy)和超大分割(UHF-RT:≥5Gy)。

主要发现

  • 放疗时中位年龄92岁(范围90–101岁),42%接受根治性放疗,58%接受姑息性放疗。
  • 全部患者中位总生存11个月(姑息治疗7个月),1年和5年总生存率分别为47%和11%。
  • 总体症状改善记录于73%患者,肿瘤相关出血改善95%、溃疡80%、疼痛65%。
  • 急性≥2级毒性发生率为21%(3级为5%)。
  • 调整混杂因素后,HF-RT和UHF-RT的全因死亡风险较NF-RT仅轻度升高。

关键数值与推荐

  • 分次分类标准:NF-RT(常规分割)、HF-RT(单次>2Gy)、UHF-RT(单次≥5Gy)。
  • 症状改善率:总体73%,出血95%,溃疡80%,疼痛65%。
  • 急性毒性:≥2级21%,3级5%。
  • 生存:中位总生存11个月(姑息7个月),1年47%,5年11%。

临床怎么用

  • 对90岁以上患者可考虑大分割或超大分割放疗以降低治疗负担。
  • 放疗对肿瘤相关出血、溃疡和疼痛有较高缓解率。
  • 需注意急性≥2级毒性风险,尤其是常规分割方案。

局限性

  • 单中心回顾性设计,存在选择偏倚和混杂因素。
  • UHF-RT和HF-RT组接受较低EQD2剂量和较小靶区体积。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Advances in radiotherapy (RT) techniques have facilitated the increasing use of hypofractionated treatment schedules, which may be particularly advantageous for elderly patients by reducing treatment burden while maintaining acceptable toxicity. This study aimed to evaluate survival and symptom palliation and to investigate whether different fractionation approaches affected toxicity and clinical outcomes in nonagenarian patients. MATERIALS AND METHODS: This single-center retrospective cohort included 199 nonagenarians treated with RT between 2005 and 2023. Fractionation was classified as normofractionated (NF-RT), hypofractionated (HF-RT: >2Gy) and ultra-hypofractionated (UHF-RT: ≥5Gy). Outcomes were symptom control, acute ≥ Grade 2 (G2) toxicity, and overall survival (OS). RESULTS: Median age at RT was 92 years (range 90-101); 42% received curative and 58% palliative RT. Median OS of all patients was 11 months (palliative treatment: 7 months), with 1- and 5-year OS rates of 47% and 11% respectively. Overall, symptom improvement was documented in 73% of patients, with particularly high frequencies of improvement in tumor-related bleeding (95%) and ulceration (80%), pain improved in 65%. Acute ≥ G2 toxicity occurred in 21% (G3, 5%). Generally, UHF-RT and HF-RT had lower odds of ≥ G2 toxicity than NF-RT, however they were treated with lower doses (EQD2) to smaller target volumes. After adjustment for confounding factors, the hazards for all-cause death were only slightly higher for HF-RT and UHF-RT compared to NF-RT. Oligometastatic patients had almost identical survival as those without metastases, patients with breast cancer had a better survival than those with other entities. CONCLUSION: RT in selected nonagenarians achieved high frequencies of palliation with low severe toxicity. Hypofractionation was well tolerated without clear impact on survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gruber G, Kasassov CM, Aigner A, et al. Radiotherapy at the limits of age: evolving fractionation strategies, symptom palliation, and survival in nonagenarians. Radiother Oncol. 2026. PMID: 42176780. doi:10.1016/j.radonc.2026.111611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。